NEW YORK--(BUSINESS WIRE)--Pluristem Therapeutics Inc. (NasdaqCM: PSTI) (DAX: PJT), a bio-therapeutics company dedicated to the commercialization of unrelated donor-patient (allogeneic) cell therapy products for a variety of disorders, announced today that the Company has completed several key initiatives in preparation for the upcoming clinical trial in Germany using the Company’s placental-derived stem cell product candidate, PLX-PAD. The initiatives included a real time check (dry run) of PLX-PAD preparation for injection, a proceeding performed at Pharmicell, which was overviewed by Pluristem's team. In addition, the process flow between Pluristem and Pharmicell and the procedures of cell delivery to the clinical sites, Charité – Universitätsmedizin Berlin and Franziskus-Krankenhaus Hospital, were reviewed and verified.
